68 filings
8-K
AXIM
Axim Biotechnologies, Inc.
21 Mar 24
Entry into a Material Definitive Agreement
3:47pm
8-K
AXIM
Axim Biotechnologies, Inc.
13 Feb 24
Entry into a Material Definitive Agreement
5:16pm
8-K
AXIM
Axim Biotechnologies, Inc.
28 Dec 23
Entry into a Material Definitive Agreement
11:59am
8-K
AXIM
Axim Biotechnologies, Inc.
2 Jun 23
Entry into a Material Definitive Agreement
2:51pm
8-K
AXIM
Axim Biotechnologies, Inc.
30 May 23
Entry into a Material Definitive Agreement
3:50pm
8-K
b3d2 5fcu5xq1wffu
25 May 23
Departure of Directors or Certain Officers
4:04pm
8-K
3qpvf8
27 Jan 23
Entry into a Material Definitive Agreement
4:07pm
8-K
8646cgve q39eirq7jx
19 Sep 22
Company to Sell, Distribute AXIM’s Readers and Three Proprietary Tests Designed for Diagnosis of Dry Eye Disease Globally Through New Agreement
4:14pm
8-K
22rjf02x2blp6wnj
29 Aug 22
Entry into a Material Definitive Agreement
3:08pm
8-K
q43joss95 evdl7ywvo
9 Mar 22
AXIM Biotech Launches For Research Use Only Sales for its COVID-19 Neutralizing Antibody Test
4:37pm
8-K
s2yek vf80nz
16 Feb 22
Entry into a Material Definitive Agreement
4:33pm
8-K
bk03mfnud87l5w
12 Jan 22
Departure of Directors or Certain Officers
12:00am
8-K
gtt7bcvi
7 Jan 22
Departure of Directors or Certain Officers
4:21pm
8-K
t89t4m8
4 Aug 21
AXIM® Biotechnologies to Acquire Technology Including Two FDA-Cleared 510(k)’s for Diagnostic Testing of Dry Eye Disease
12:00am
8-K
z02jtlsbu 3pm
14 May 21
Entry into a Material Definitive Agreement
4:07pm
8-K
n2cw20b6
24 Jul 20
Departure of Directors or Certain Officers
12:00am
8-K/A
6uxqdxpzd7c0l9ps5s
29 May 20
Index to Combined Financial Statements
12:00am
8-K
m2ndm
14 May 20
Other Events
5:06pm
8-K
vkjo2rpgme50
13 May 20
AXIM® Biotechnologies Issues Update Letter to Shareholders
12:00am
8-K
dmbu6ar9sigqogw
12 May 20
Entry into a Material Definitive Agreement
5:02pm